Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

R. Krishna, Carol L Addy, +11 authors Selwyn Aubrey Stoch
Published 2016 in Journal of clinical pharmacology

Abstract

The pharmacokinetics (PK) and pharmacodynamics (PD) of omarigliptin, a novel once-weekly DPP-4 inhibitor, were assessed following single and multiple doses in healthy subjects. Absorption was rapid, and food did not influence single-dose PK. Accumulation was minimal, and steady state was reached after 2 to 3 weeks. Weekly (area under the curve) AUC and Cmax… (More)

DOI: 10.1002/jcph.773

Topics

6 Figures and Tables

Cited By

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control

Ira Gantz, Taro Okamoto, +5 authors Eseng Lai
Diabetes therapy : research, treatment and…
2017

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

R Ravi Shankar, Silvio E Inzucchi, +6 authors Samuel S Engel
Current medical research and opinion
2017

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men

Saori Tsuchiya, Evan Friedman, +5 authors Eunkyung Kauh
Journal of diabetes investigation
2017

References

Sort by:

Showing 1-10 of 15 references

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.

Daniel A Tatosian, Nadia Cardillo Marricco, +7 authors Eunkyung Kauh
Clinical pharmacology in drug development
2016

Scheen AJ
Expert Opin Pharmacother
2015

Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.

B Darpo, C Benson, +15 authors N Stockbridge
Clinical pharmacology and therapeutics
2015

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Tesfaye Biftu, Ranabir Sinha-Roy, +26 authors Ann E Weber
Journal of medicinal chemistry
2014

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.

Stephen S Johnston, Hiep Nguyen, +4 authors Iftekhar Kalsekar
Advances in therapy
2014

IDF Diabetes Atlas
Brussels, Belgium: International Diabetes…
2013

Brubaker PL
2010

Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.

Shashank Rohatagi, Timothy J Carrothers, Jon Kuwabara-Wagg, Tatiana Khariton
Journal of clinical pharmacology
2009

Model-based evaluation of QTc interval risk: an increasing emphasis on early decision making.

Rajesh Krishna
Journal of clinical pharmacology
2009

The incretin system and its role in type 2 diabetes mellitus.

Jens Juul Holst, Tina Vilsbøll, Carolyn F Deacon
Molecular and cellular endocrinology
2009

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

Abstract

Topics

6 Figures and Tables

Cited By

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men

References

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.

A review of gliptins for 2014

Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.

6th ed

Mini review: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology

Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.

Model-based evaluation of QTc interval risk: an increasing emphasis on early decision making.

The incretin system and its role in type 2 diabetes mellitus.

Slides referencing similar topics

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

Abstract

Topics

6 Figures and Tables

Cited By

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men

References

A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.

A review of gliptins for 2014

Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.

6th ed

Mini review: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology

Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.

Model-based evaluation of QTc interval risk: an increasing emphasis on early decision making.

The incretin system and its role in type 2 diabetes mellitus.

Similar Papers

Slides referencing similar topics